Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.
Cellectis S.A. (CLLS) news covers the activities of a clinical-stage biotechnology company focused on gene-edited cell and gene therapies. The company regularly issues updates on its allogeneic CAR-T pipeline, gene-editing technology advances, strategic collaborations, and financial position, providing a detailed view of how its programs evolve over time.
Investors and observers following Cellectis news can read about clinical data from key trials such as BALLI-01 for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia and NATHALI-01 for eti-cel (UCART20x22) in relapsed/refractory non-Hodgkin lymphoma. Press releases describe response rates, safety findings, and trial design features, as well as plans for pivotal Phase 2 development and data presentations at major scientific meetings.
Cellectis also publishes research and technology updates, including work on circular single-stranded DNA (CssDNA) as a non-viral donor template for gene insertion in hematopoietic stem and progenitor cells and studies of TALE base editors in primary T cells. These announcements highlight how the company applies its gene-editing platform beyond CAR-T therapies.
Additional news items address collaborations with partners such as AstraZeneca, Servier, Allogene, and Iovance, along with arbitration outcomes, financial results, cash runway disclosures, and monthly information on share capital and voting rights. By reviewing this news feed, readers can track both scientific progress and corporate developments that shape the outlook for Cellectis and its CLLS listing.
Cellectis (CLLS) has released its monthly share capital and voting rights information as of July 31, 2024, in compliance with French financial market regulations. The report indicates that the total number of shares in the capital is 100,093,635, while the total number of voting rights stands at 88,029,164. This information is important for investors to understand the company's ownership structure and potential voting power distribution.
The press release provides contact details for media and investor relations, including Pascalyne Wilson (Director of Communications) and Arthur Stril (Interim Chief Financial Officer). This transparency in reporting and accessibility to company representatives demonstrates Cellectis' commitment to maintaining open communication channels with stakeholders and complying with regulatory requirements.
Cellectis (NASDAQ: CLLS) announced that the FDA has granted Orphan Drug Designation (ODD) to CLLS52 (alemtuzumab), used in the lymphodepletion regimen for UCART22 in the BALLI-01 clinical trial for relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). The addition of alemtuzumab to the fludarabine and cyclophosphamide regimen has shown sustained lymphodepletion and higher UCART22 cell expansion, leading to greater clinical activity.
Cellectis invented the combination of CD52 knockout UCART cells with a lymphodepleting regimen containing an anti-CD52 antibody. The CD52 knockout aims to make UCART products resistant to alemtuzumab. ODD status may help expedite and reduce costs for development, approval, and commercialization of CLLS52 for ALL treatment.
Cellectis (NASDAQ: CLLS) announced that the FDA has granted Orphan Drug (ODD) and Rare Pediatric Disease Designation (RPDD) Status to its UCART22 product candidate for treating Acute Lymphoblastic Leukemia (ALL). ALL represents 10% of leukemia cases in the US, progressing rapidly and often fatal if untreated. The designations highlight UCART22's potential to address urgent needs in ALL treatment, especially for patients ineligible for stem cell transplantation or relapsing after other therapies.
UCART22, an allogeneic CAR T-cell therapy, is being evaluated in the BALLI-01 Phase 1/2 study. Recent data showed a 67% preliminary response rate at Dose Level 2 for UCART22-P2, manufactured by Cellectis. The company expects to provide updates on BALLI-01 by year-end 2024. These FDA designations may expedite development and reduce costs for UCART22.
On July 5, 2024, Cellectis provided an update on its share capital and voting rights as required by Article 223-16 of the French financial markets authority.
The company, listed on the Euronext Growth market under ISIN code FR0010425595, reported a total of 100,093,635 shares in its capital as of June 30, 2024.
The total number of voting rights for the same period was 88,029,364.
For any queries, media can contact Pascalyne Wilson, Director of Communications, or Patricia Sosa Navarro, Chief of Staff to the CEO. Investor relations are managed by Arthur Stril, Interim CFO, and Ashley R. Robinson from LifeSci Advisors.
Cellectis, a clinical-stage biotechnology company listed on Euronext Growth (ALCLS) and Nasdaq (CLLS), held its shareholders' general meeting on June 28, 2024, in Paris. Approximately 40% of shares were exercised during the meeting, resulting in the adoption of resolutions 1 through 28 and the rejection of resolution 29, aligning with management's recommendations. Detailed voting results and resolutions are accessible on Cellectis' official website.
Cellectis, a clinical-stage biotechnology company, has published a scientific article in Scientific Reports, revealing three key factors for efficient TALE base editing. This gene-editing technology, which does not create DNA breaks like CRISPR/Cas9, holds promise for treating genetic diseases by converting cytosine (C) to thymine (T). The study identifies spacer length, TALEB architecture, and surrounding base composition as critical elements for enhancing editing efficiency. This research deepens the understanding of TALE base editors, potentially expanding their therapeutic applications. The full article is available on the Scientific Reports website.
Cellectis announced a breakthrough in gene therapy for Sickle Cell Disease (SCD) using a non-viral approach published in Nature Communications. The therapy employs TALEN® technology for precise HBB gene correction in hematopoietic stem and progenitor cells (HSPCs). This method achieves over 50% expression of normal hemoglobin in treated cells, effectively correcting the sickle cell phenotype without adverse effects. The preclinical data shows promising therapeutic potential and efficient engraftment in animal models, indicating readiness for clinical application. This innovative approach offers hope for addressing SCD and other genetic diseases.
Cellectis has released its monthly update on share capital and voting rights as of May 31, 2024. The company, listed on Euronext Growth with ISIN code FR0010425595, reports a total of 100,093,635 shares in its capital. The number of voting rights stands at 88,029,374. For more details, media and investor relations contacts are provided.
Cellectis announced that the European Commission granted Orphan Drug Designation (ODD) to UCART22, its allogeneic CAR T product for treating Acute Lymphoblastic Leukemia (ALL).
UCART22 targets CD22 and is being evaluated in the Phase 1/2 BALLI-01 study, focusing on patients with relapsed/refractory ALL.
ALL accounts for 12% of all leukemia cases and progresses rapidly. The 10-year prevalence in the EU is estimated at 1.9 per 100,000 persons.
The ODD was based on preliminary clinical data showing UCART22's significant benefit in heavily pretreated patients. In December 2023, Cellectis reported encouraging data with a 67% response rate at Dose Level 2 for UCART22-P2.
ODD provides regulatory, financial, and commercial incentives.
Cellectis (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET.
The meeting will take place at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Details regarding the agenda and participation are available on the Cellectis website.